Is IR MED Inc (OTC-IRME) undervalued or overvalued?

A clear undervalued or overvalued classification is not currently available in the latest data file.

How is the financial health of IR MED Inc?

The current financial health read for IR MED Inc (OTC-IRME) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is IR MED Inc's next earnings date?

The next earnings date currently listed for IR MED Inc (OTC-IRME) is September 2, 2026.

Does IR MED Inc (OTC-IRME) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for IR MED Inc (OTC-IRME)?

The current P/E ratio listed for IR MED Inc (OTC-IRME) is -0.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of IR MED Inc?

The current market capitalization listed for IR MED Inc is 122.593 K.

What is the enterprise value of IR MED Inc?

The current enterprise value listed for IR MED Inc is 967.138 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for IR MED Inc?

The ticker symbol for IR MED Inc is OTC-IRME, and the stock is listed on OTC Markets.

Where is IR MED Inc (OTC-IRME) listed?

IR MED Inc (OTC-IRME) is listed on OTC Markets.

What is the debt-to-total-capital ratio for IR MED Inc?

The current debt-to-total-capital ratio listed for IR MED Inc is 24.3%, which helps investors evaluate the company’s financing structure and leverage profile.

IR MED Inc (IRME) Fair Value & Stock Analysis

Q: What is the fair value of IR MED Inc (OTC-IRME) stock?

A fair value estimate for IR MED Inc (OTC-IRME) is not currently available in the latest data file.

Q: What is the analyst price target for OTC-IRME stock?

An analyst price target for IR MED Inc (OTC-IRME) is not currently available in the latest data file.

IR MED Inc (IRME)

IR-Med Inc. is a healthcare company focused on developing non-invasive medical devices for a range of clinical uses. Its development pipeline includes PressureSafe, a handheld optical monitoring device intended to support early identification of pressure injuries to the skin and underlying tissue associated with prolonged pressure during bed confinement. The company is also developing DiaSafe, a handheld optical monitoring device designed to help detect diabetic foot ulcers in the lower limb, and Nobiotics, an otoscope intended to provide physicians with an immediate indication of middle-ear conditions in children. IR-Med is headquartered in Rosh Pinna, Israel, and its common stock trades on OTC Markets under the symbol IRME.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-IRME	—	—	—	—	—	—	Weak	—	—	—	0.0%	September 2, 2026	-0.3x	-1.2x	—	122.593 K	967.138 K	24.3%	—	-418.7	—	35.6%